Pages that link to "Q44226733"
Jump to navigation
Jump to search
The following pages link to Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection (Q44226733):
Displaying 50 items.
- A Practical Approach to Management of Chronic Hepatitis B (Q24810145) (← links)
- KASL clinical practice guidelines: management of chronic hepatitis B (Q26752475) (← links)
- Management of patients with hepatitis B who require immunosuppressive therapy (Q26853490) (← links)
- Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings (Q28540372) (← links)
- A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B (Q28741501) (← links)
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. (Q30391932) (← links)
- Current hepatitis B treatment guidelines and future research directions (Q30487002) (← links)
- Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. (Q33718958) (← links)
- Evaluation of the COBAS amplicor HBV monitor assay and comparison with the ultrasensitive HBV hybrid capture 2 assay for quantification of hepatitis B virus DNA (Q33825842) (← links)
- Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines (Q33855708) (← links)
- A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. (Q33959934) (← links)
- Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit (Q34137291) (← links)
- Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B. (Q34173092) (← links)
- A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. (Q34184642) (← links)
- Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practice (Q34256062) (← links)
- Outbreak of hepatitis B virus infections associated with assisted monitoring of blood glucose in an assisted living facility-Virginia, 2010. (Q34539997) (← links)
- Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections (Q34683065) (← links)
- The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience (Q35495205) (← links)
- Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients (Q35589366) (← links)
- Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. (Q35596851) (← links)
- Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications (Q35597930) (← links)
- Viral hepatitis B. (Q35617319) (← links)
- Management of hepatitis B in developing countries (Q35635637) (← links)
- Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion (Q35840358) (← links)
- A low proportion of HBeAg among HBsAg-positive pregnant women with known HIV status could suggest low perinatal transmission of HBV in Cameroon (Q35861676) (← links)
- High hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study (Q35950941) (← links)
- MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosis (Q36146616) (← links)
- KASL Clinical Practice Guidelines: Management of chronic hepatitis B. (Q36153966) (← links)
- The laboratory diagnosis of hepatitis B virus (Q36171000) (← links)
- A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa (Q36184624) (← links)
- Predicting survival in hepatitis B. (Q36287594) (← links)
- Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. (Q36382269) (← links)
- Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients (Q36391991) (← links)
- New developments in the treatment of chronic hepatitis B. (Q36569744) (← links)
- Lamivudine treatment in patients with chronic hepatitis B and cirrhosis (Q36573919) (← links)
- Recommendations and potential future options in the treatment of hepatitis B. (Q36632233) (← links)
- Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma (Q36724380) (← links)
- Management of patients with HBeAg-negative chronic hepatitis B (Q36724421) (← links)
- Correlation between viral load of HBV in chronic hepatitis B patients and precore and Basal core promoter mutations (Q36771263) (← links)
- Molecular testing in the diagnosis and management of chronic hepatitis B (Q36881140) (← links)
- Evaluation of a new hepatitis B virus surface antigen rapid test with improved sensitivity. (Q36933452) (← links)
- The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis (Q37111755) (← links)
- Histological grading and staging of liver and its relation to viral loads in chronic anti-HBe positive hepatitis (Q37128478) (← links)
- Evaluation of the need for treatment on 72 subjects with anti-HBe positive chronic hepatitis B. (Q37128552) (← links)
- The correlation between serum HBsAg levels and viral loads depends upon wild-type and mutated HBV sequences rather than the HBeAg/anti-HBe status (Q37166945) (← links)
- Treatment of chronic hepatitis B infection: an update of Swedish recommendations (Q37201573) (← links)
- Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma (Q37214128) (← links)
- Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers (Q37241959) (← links)
- Characteristics of treatment naïve chronic hepatitis B in Bangladesh: younger populations are more affected; HBeAg-negatives are more advanced (Q37243531) (← links)
- Dual oncogenic and tumor suppressor roles of the promyelocytic leukemia gene in hepatocarcinogenesis associated with hepatitis B virus surface antigen (Q37317562) (← links)